OverviewSuggest Edit

PPD (Pharmaceutical Product Development) is a contract research organization that provides drug development services to the biopharmaceutical industry. It delivers clinical development and laboratory services to pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants.

TypePublic
Founded1985
HQWilmington, NC, US
Websiteppd.com
Employee Ratings3.7
Overall CultureC-

Latest Updates

Employees (est.) (Dec 2020)26,000(+14%)
Job Openings2,250
Revenue (FY, 2020)$4.7 B(+17%)
Share Price (Jun 2021)$46.5
Cybersecurity ratingDMore

Key People/Management at PPD

David Simmons

David Simmons

Chairman and Chief Executive Officer
William Sharbaugh

William Sharbaugh

Chief Operating Officer
Glen Donovan

Glen Donovan

Chief Accounting Officer
Judd Hartman

Judd Hartman

Executive Vice President and Chief Administrative Officer
Tracy Krumme

Tracy Krumme

Vice President, Head of Investor Relations
Ron Garrow

Ron Garrow

Executive Vice President and Chief Human Resource Officer
Show more

PPD Office Locations

PPD has offices in Wilmington, Austin, Hamilton Township, Highland Heights and in 63 other locations
Wilmington, NC, US (HQ)
PPD Building, 929 N Front St
Austin, TX, US
7551 Metro Center Dr #200
Hamilton Township, NJ, US
3575 Quakerbridge Rd
Highland Heights, KY, US
2 Tesseneer Rd
Horsham, PA, US
132 Welsh Rd
Las Vegas, NV, US
8285 W Arby Ave #331
Show all (75)

PPD Financials and Metrics

PPD Revenue

Embed Graph
View revenue for all periods
PPD's revenue was reported to be $4.68 b in FY, 2020 which is a 16.1% increase from the previous period.
USD

Revenue (FY, 2020)

4.7b

Revenue growth (FY, 2019 - FY, 2020), %

16.1%

Gross profit (FY, 2020)

3.0b

Gross profit margin (FY, 2020), %

64.1%

Net income (FY, 2020)

160.6m

EBIT (FY, 2020)

508.0m

Market capitalization (14-Jun-2021)

16.3b

Closing stock price (14-Jun-2021)

46.5

Cash (31-Dec-2020)

768.0m

EV

20.0b
PPD's current market capitalization is $16.3 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

3.7b4.0b4.7b

Revenue growth, %

25%8%16%

Cost of goods sold

1.3b1.5b1.7b

Gross profit

2.4b2.5b3.0b
Quarterly
USDQ1, 2020Q2, 2020Q3, 2020

Revenue

1.1b1.0b1.2b

Cost of goods sold

414.4m374.8m433.4m

Gross profit

658.0m636.1m800.4m

Gross profit Margin, %

61%63%65%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

553.1m345.2m768.0m

Accounts Receivable

1.3b1.3b1.6b

Prepaid Expenses

146.1m

Current Assets

1.9b1.8b2.5b
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

403.4m738.4m693.0m803.1m

Accounts Receivable

1.3b1.4b

Prepaid Expenses

117.1m122.0m

Current Assets

1.9b2.2b2.2b2.4b
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

300.8m106.9m52.8m160.6m

Depreciation and Amortization

279.1m259.0m264.8m279.1m

Accounts Payable

103.0m(4.4m)26.3m141.2m

Cash From Operating Activities

359.1m423.4m432.9m251.3m
Quarterly
USDQ3, 2018Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

92.1m34.5m(13.1m)49.0m58.1m

Depreciation and Amortization

195.3m197.9m66.3m135.1m206.4m

Accounts Payable

(36.5m)12.5m(48.1m)(22.3m)116.5m

Cash From Operating Activities

301.1m313.7m19.4m130.8m268.5m
Show all financial metrics

PPD Operating Metrics

PPD's Backlog was reported to be $8.2b in FY, 2020.
FY, 2018Q1, 2019FY, 2019Q1, 2020Q2, 2020Q3, 2020FY, 2020

Backlog

$6.31 b$6.53 b$7.07 b$7.31 b$7.58 b$7.89 b$8.19 b

Clinical Trials

2.1 k

Countries

4646

Offices

100
Show all operating metrics

PPD Acquisitions / Subsidiaries

Company NameDateDeal Size
Synarc Inc.September 03, 2019$45.2 m
Medimix InternationalJuly 01, 2019$36.8 m
Optimal ResearchSeptember 01, 2017$24 m
EvideraAugust 09, 2016
SynexusJune 06, 2016
X-ChemSeptember 26, 2014
RCT LogicSeptember 03, 2014
Bioduro-SundiaNovember 18, 2009
Excel PharmaStudiesOctober 01, 2009
AbCROApril 21, 2009
Show more

PPD Revenue Breakdown

Embed Graph

PPD revenue breakdown by geographic segment: 56.5% from North America, 28.8% from Europe, Middle East and Africa, 10.9% from Asia-Pacific and 3.8% from Other

PPD Cybersecurity Score

Cybersecurity ratingPremium dataset

D

67/100

SecurityScorecard logo

PPD Online and Social Media Presence

Embed Graph

PPD Company Culture

  • Overall Culture

    C-

    62/100

  • CEO Rating

    C

    65/100

  • Compensation

    D+

    56/100

  • Diversity

    C-

    60/100

Learn more on Comparably

PPD News and Updates

Ppd Named ‘Most Innovative Cro’ by Triangle Business Journal

PPD, Inc. (Nasdaq: PPD) has been named “Most Innovative CRO” by North Carolina’s Triangle Business Journal, recognizing the global contract research organization’s strong performance in a year shaped by the COVID-19 pandemic

Ppd Opens Multipurpose Clinical Research Laboratory in Suzhou, China

PPD held a grand opening ceremony for its new multipurpose laboratory in Suzhou, China, to support Western and China-based pharmaceutical and biotech companies managing China research studies.

CRO Leadership Awards Recognize PPD for Excellence for 10th Consecutive Year

PPD, Inc. (Nasdaq: PPD) has been recognized for excellence in the CRO Leadership Awards for the 10th consecutive year, earning praise for its clinical research capabilities and customer compatibility in a survey of pharmaceutical and biotech professionals conducted for Clinical Leader and Life Scien…

PPD Named “Best CRO” at Vaccine Industry Excellence Awards

PPD, Inc. (Nasdaq: PPD) was named “Best Contract Research Organization” at the 14th annual Vaccine Industry Excellence (ViE) Awards during the 2021 World Vaccine Congress. Accelerated Enrollment Solutions (AES), a business of PPD, received the honor of “highly commended” in the category of “Best Cli…

PPD to Expand GMP Lab in Ireland to Enhance Biopharmaceutical Testing Capabilities

PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, is expanding its Athlone, Ireland, GMP (good manufacturing practices) laboratory, significantly increasing the size of its current facility and adding cell and gene therapy testing to the operation’s portfolio of services.

PPD Reports First Quarter 2021 Results

PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, today reported its financial results for the first quarter ended March 31, 2021.
Show more

PPD Blogs

PPD Named ‘Most Innovative CRO’ by Triangle Business Journal

PPD Named ‘Most Innovative CRO’ by Triangle Business Journal randy.buckwalt… Thu, 05/27/2021 - 09:02 PPD Named ‘Most Innovative CRO’ by Triangle Business Journal May 27, 2021 at 9:00 AM EDT This release is a backfill from a News Wire General …

CRO Leadership Awards Recognize PPD for Excellence for 10th Consecutive Year

CRO Leadership Awards Recognize PPD for Excellence for 10th Consecutive Year randy.buckwalt… Thu, 05/20/2021 - 09:02 CRO Leadership Awards Recognize PPD for Excellence for 10th Consecutive Year May 20, 2021 at 9:00 AM EDT This release is a backfill from a News…

PPD Named “Best CRO” at Vaccine Industry Excellence Awards

PPD Named “Best CRO” at Vaccine Industry Excellence Awards eileen.white@i… Thu, 05/06/2021 - 08:31 PPD Named “Best CRO” at Vaccine Industry Excellence Awards May 6, 2021 at 8:30 AM EDT This release is a backfill from a News Wire General …

PPD to Expand GMP Lab in Ireland to Enhance Biopharmaceutical Testing Capabilities

PPD to Expand GMP Lab in Ireland to Enhance Biopharmaceutical Testing Capabilities eileen.white@i… Wed, 04/28/2021 - 09:00 PPD to Expand GMP Lab in Ireland to Enhance Biopharmaceutical Testing Capabilities April 28, 2021 at 9:00 AM EDT This release is a backfi…

PPD Reports First Quarter 2021 Results

PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, today reported its financial results for the first quarter ended March 31, 2021.

PPD and Science 37® Strengthen Collaboration to Advance Decentralized Clinical Trials and Accelerate Development

PPD, Inc. (Nasdaq: PPD), a leading global contract research organization (CRO), and Science 37, developer of the Decentralized Clinical Trial Operating System™ (DCT OS), today announced an innovative collaboration in which PPD will be fully enabled to design, build, test, implement and execute digit…
Show more

PPD Frequently Asked Questions

  • When was PPD founded?

    PPD was founded in 1985.

  • Who are PPD key executives?

    PPD's key executives are David Simmons, William Sharbaugh and Glen Donovan.

  • How many employees does PPD have?

    PPD has 26,000 employees.

  • What is PPD revenue?

    Latest PPD annual revenue is $4.7 b.

  • What is PPD revenue per employee?

    Latest PPD revenue per employee is $180.1 k.

  • Who are PPD competitors?

    Competitors of PPD include Eurofins, Parexel International and PRA Health Sciences.

  • Where is PPD headquarters?

    PPD headquarters is located at PPD Building, 929 N Front St, Wilmington.

  • Where are PPD offices?

    PPD has offices in Wilmington, Austin, Hamilton Township, Highland Heights and in 63 other locations.

  • How many offices does PPD have?

    PPD has 75 offices.